Nothing Special   »   [go: up one dir, main page]

CY1120369T1 - Θεραπεια νευρολογικων διαταραχων βασει βακλοφαινης και ακαμπροσατης - Google Patents

Θεραπεια νευρολογικων διαταραχων βασει βακλοφαινης και ακαμπροσατης

Info

Publication number
CY1120369T1
CY1120369T1 CY20181100664T CY181100664T CY1120369T1 CY 1120369 T1 CY1120369 T1 CY 1120369T1 CY 20181100664 T CY20181100664 T CY 20181100664T CY 181100664 T CY181100664 T CY 181100664T CY 1120369 T1 CY1120369 T1 CY 1120369T1
Authority
CY
Cyprus
Prior art keywords
disease
vaclophine
laboratory
neurological disorder
treatment based
Prior art date
Application number
CY20181100664T
Other languages
English (en)
Inventor
Daniel Cohen
Ilya Chumakov
Serguei Nabirochkin
Emmanuel Vial
Mickaël GUEDJ
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of CY1120369T1 publication Critical patent/CY1120369T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε συνδυασμούς και μεθόδους για την αγωγή νευρολογικών διαταραχών που σχετίζονται με διεγερτοτοξικότητα γλουταμινικού και τοξικότητα β αμυλοειδούς. Ειδικότερα, η παρούσα εφεύρεση αναφέρεται σε νέες συνδυαστικές θεραπείες της σκληρύνσεως κατά πλάκας, της νόσου Alzheimer, της σχετιζόμενης με νόσο Alzheimer διαταραχής, της αμυοτροφικής πλάγιας σκληρύνσεως, της νόσου Parkinson, της νόσου του Huntington, του νευροπαθούς άλγους, της αλκοολικής νευροπάθειας, του αλκοολισμού ή της αλκοολικής στερήσεως ή της κακώσεως του νωτιαίου μυελού βάσει του συνδυασμού βακλοφαίνης και ακαμπροσάτης.
CY20181100664T 2011-03-01 2018-06-27 Θεραπεια νευρολογικων διαταραχων βασει βακλοφαινης και ακαμπροσατης CY1120369T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP11305217 2011-03-01
US201161468658P 2011-03-29 2011-03-29
US201161493606P 2011-06-06 2011-06-06
EP11305687 2011-06-06
EP13196468.6A EP2796132B1 (en) 2011-03-01 2012-03-01 Baclofen and acamprosate based therapy of neurological disorders
EP12708113.1A EP2560631B1 (en) 2011-03-01 2012-03-01 Baclofen and acamprosate based therapy of neurogical disorders

Publications (1)

Publication Number Publication Date
CY1120369T1 true CY1120369T1 (el) 2019-07-10

Family

ID=46758335

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20141100159T CY1115074T1 (el) 2011-03-01 2014-02-27 Θεραπεια νευρολογικων διαταραχων βασει βακλοφαινης και ακαμπροσατης
CY20181100664T CY1120369T1 (el) 2011-03-01 2018-06-27 Θεραπεια νευρολογικων διαταραχων βασει βακλοφαινης και ακαμπροσατης
CY181101262T CY1120925T1 (el) 2011-03-01 2018-11-28 Θεραπεια νευρολογικων διαταραχων βασει βακλοφαινης και ακαμπροσατης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20141100159T CY1115074T1 (el) 2011-03-01 2014-02-27 Θεραπεια νευρολογικων διαταραχων βασει βακλοφαινης και ακαμπροσατης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY181101262T CY1120925T1 (el) 2011-03-01 2018-11-28 Θεραπεια νευρολογικων διαταραχων βασει βακλοφαινης και ακαμπροσατης

Country Status (27)

Country Link
US (7) US9820978B2 (el)
EP (5) EP3332781A1 (el)
JP (2) JP5987008B2 (el)
KR (2) KR101918745B1 (el)
CN (2) CN105997969B (el)
AU (2) AU2012222351B2 (el)
BR (1) BR112013022112B1 (el)
CA (1) CA2828765C (el)
CY (3) CY1115074T1 (el)
DK (3) DK2727588T3 (el)
EA (2) EA023277B1 (el)
ES (5) ES2450074T3 (el)
HK (2) HK1182615A1 (el)
HR (1) HRP20140131T1 (el)
HU (1) HUE038653T2 (el)
IL (2) IL228177B (el)
LT (2) LT2796132T (el)
MX (1) MX340568B (el)
PL (3) PL2727588T3 (el)
PT (1) PT2560631E (el)
RS (3) RS58114B1 (el)
SG (2) SG192968A1 (el)
SI (3) SI2727588T1 (el)
SM (1) SMT201400029B (el)
TR (1) TR201809351T4 (el)
WO (2) WO2012117076A2 (el)
ZA (1) ZA201306039B (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
CN104487064B (zh) * 2012-03-01 2018-01-26 法耐斯特公司 用于治疗肌萎缩性侧索硬化症的新组合物
US9867837B2 (en) * 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
UA113165C2 (xx) * 2011-03-01 2016-12-26 Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
US9248111B2 (en) * 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
LT2796132T (lt) 2011-03-01 2018-10-10 Pharnext Neurologinių sutrikimų terapija baklofeno ir akamprosato pagrindu
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
GB2501457A (en) 2012-02-10 2013-10-30 Rational Intellectual Holdings Ltd Assigning player positions in an online table game
SI2819664T1 (sl) * 2012-03-01 2017-12-29 Pharnext Novi sestavki za zdravljenje amiotrofične lateralne skleroze
AU2013224959B2 (en) * 2012-03-01 2017-12-07 Pharnext New compositions for treating amyotrophic lateral sclerosis
AU2013291970B2 (en) * 2012-07-18 2017-09-28 Pharnext Baclofen and acamprosate based therapy of Macular Degeneration disorders
EP2705841A1 (en) * 2012-09-05 2014-03-12 Pharnext Combinations of nootropic agents for treating cognitive dysfunctions
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
EP3003268B1 (en) 2013-06-05 2018-07-25 Pharnext Stable oral solutions for combined api
BR112015031835B1 (pt) 2013-06-19 2022-12-13 Som Innovation Biotech, S.L Usos de agentes terapêuticos, de uma combinação dos referidos agentes com um agente terapêutico adicional, e de uma composição farmacêutica para fabricação de medicamento para a profilaxia e/ou tratamento de distúrbios do movimento hipercinético
KR102206745B1 (ko) * 2013-07-12 2021-02-03 경상대학교산학협력단 안토시아닌 및 gabab 수용체 작용제를 유효성분으로 포함하는 신경질환 치료제
WO2015023830A1 (en) 2013-08-14 2015-02-19 Stc.Unm Treatment and prevention of stroke and other neurological disorders
WO2015063140A1 (en) * 2013-10-30 2015-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
EA201691602A1 (ru) * 2014-02-11 2017-03-31 Фарнекст Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств
EP3616686B8 (en) * 2014-11-21 2021-06-23 Biohaven Pharmaceutical Holding Company Ltd. Sublingual formulation of riluzole
WO2016179252A1 (en) 2015-05-04 2016-11-10 Confluence Pharmaceuticals, Llc Sprinkle formulations of acamprosate
EP3156050A1 (en) * 2015-10-16 2017-04-19 Universitat Autònoma De Barcelona New combination therapies for treating neurological damage
ES2894801T3 (es) 2015-12-29 2022-02-15 Univ Kyoto Agente para prevenir y/o tratar la enfermedad de Alzheimer
WO2017134280A1 (en) * 2016-02-05 2017-08-10 Pharnext Novel combinatorial therapies of neurological disorders
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
US10736876B2 (en) 2017-04-24 2020-08-11 Pharnext Idalopirdine-based combinatorial therapies of Alzheimer's disease
WO2018213589A1 (en) * 2017-05-17 2018-11-22 Confluence Pharmaceuticals, Llc Formulations of homotaurines and salts thereof
US11878001B2 (en) 2017-07-31 2024-01-23 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
AU2019211135A1 (en) * 2018-01-29 2020-08-06 Pharnext Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
WO2023154794A1 (en) * 2022-02-09 2023-08-17 University Of North Texas Health Science Center Drug repurposing for delayed treatment of ischemic stroke
CN115350172A (zh) * 2022-08-12 2022-11-18 昆明医科大学 Gabapentin对AD情景记忆改善的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
US6573251B2 (en) 1994-03-30 2003-06-03 Denis Barritault Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
WO2001058476A2 (en) 2000-02-11 2001-08-16 The European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
CA2452678A1 (en) 2001-07-19 2003-01-30 Pharmacia Corporation Combination of eplerenone and an hmg coa reductase inhibitor
WO2003077902A1 (en) 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US20040067918A1 (en) 2002-03-18 2004-04-08 Keller Bradley T. Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
PT1563846E (pt) 2002-10-10 2012-11-13 Ono Pharmaceutical Co Promotores da produção de factores endógenos de reparação
KR101140559B1 (ko) 2003-08-20 2012-07-05 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
US7227028B2 (en) 2003-12-30 2007-06-05 Xenoport, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
US20080025962A1 (en) 2004-11-30 2008-01-31 Angesmg,Inc. Remedy for Alzheimer's Disease
US20080188510A1 (en) 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
WO2008006070A2 (en) 2006-07-06 2008-01-10 Roskamp Research Llc Compounds and combinations thereof for inhibiting beta-amyloid production and methods of use thereof
CA2674610C (en) 2007-01-11 2013-06-18 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
MX2009012583A (es) 2007-05-22 2010-03-08 Otsuka Pharma Co Ltd Un medicamento que comprende un derivado de carbostirilo y donepezilo para tratar enfermedad de alzheimer.
WO2009033079A1 (en) 2007-09-07 2009-03-12 Xenoport, Inc. Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009033061A1 (en) 2007-09-07 2009-03-12 Xenoport, Inc. Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
TW200932734A (en) 2007-10-15 2009-08-01 Xenoport Inc Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090118365A1 (en) * 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
US20100137442A2 (en) 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
WO2009096985A1 (en) 2008-02-01 2009-08-06 Xenoport, Inc. Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment
ES2764480T3 (es) * 2008-04-29 2020-06-03 Impact Coatings Ab Composiciones de combinación para tratar la enfermedad de Alzheimer y trastornos relacionados con zonisamida y acamprosato
BRPI0911520A2 (pt) * 2008-04-29 2017-06-13 Pharnext novas aproximações terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de angiogênese.
PT2282779E (pt) * 2008-04-29 2013-05-28 Pharnext Novas abordagens terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de resposta ao stresse celular
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
CA2744857C (en) 2008-11-27 2014-02-18 National University Corporation Kagawa University Cyclobutyl purine derivative, angiogenesis promoting agent, lumen formation promoting agent, neurocyte growth promoting agent, and drug
PL2378883T3 (pl) * 2008-12-04 2016-06-30 Intec Pharma Ltd SYSTEM DOSTARCZANIA LEKU ZATRZYMYWANEGO W ŻOŁĄDKU dLA ZALEPLONU
KR20110117216A (ko) 2009-03-03 2011-10-26 제노포트 인코포레이티드 Ｒ-바클로펜 전구약물의 서방형 경구 투약 형태
WO2010120370A2 (en) 2009-04-17 2010-10-21 Xenoport, Inc. Gamma-amino-butyric acid derivatives as gabab receptor ligands
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
UA113165C2 (xx) 2011-03-01 2016-12-26 Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
LT2796132T (lt) 2011-03-01 2018-10-10 Pharnext Neurologinių sutrikimų terapija baklofeno ir akamprosato pagrindu
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9867837B2 (en) 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders

Also Published As

Publication number Publication date
DK2560631T3 (da) 2014-02-10
PL2796132T3 (pl) 2018-10-31
MX2013010043A (es) 2014-02-11
LT2796132T (lt) 2018-10-10
AU2017210501B2 (en) 2018-11-01
KR20180043844A (ko) 2018-04-30
PL2727588T3 (pl) 2019-04-30
ES2698927T3 (es) 2019-02-06
EP2560631B1 (en) 2014-01-15
IL228177B (en) 2018-01-31
CN103596562B (zh) 2016-06-01
EP2727588B1 (en) 2018-08-29
BR112013022112A2 (pt) 2018-06-26
EP2727588A1 (en) 2014-05-07
RS57426B1 (sr) 2018-09-28
KR101937782B1 (ko) 2019-01-11
HRP20140131T1 (hr) 2014-05-09
ES2450074T3 (es) 2014-03-21
US20200085790A1 (en) 2020-03-19
US8865769B2 (en) 2014-10-21
WO2012117076A2 (en) 2012-09-07
US8741886B2 (en) 2014-06-03
SG10201610587SA (en) 2017-02-27
US20140080873A1 (en) 2014-03-20
EA201891833A1 (ru) 2019-01-31
HUE038653T2 (hu) 2018-11-28
EP2796132B1 (en) 2018-05-02
CY1120925T1 (el) 2019-12-11
EP2560631A2 (en) 2013-02-27
SI2560631T1 (sl) 2014-06-30
WO2012117076A3 (en) 2012-10-26
US20130090307A1 (en) 2013-04-11
AU2017210501A1 (en) 2017-08-17
DK2796132T3 (en) 2018-07-23
CY1115074T1 (el) 2016-12-14
HK1203158A1 (en) 2015-10-23
US9636316B2 (en) 2017-05-02
ES2665569T3 (es) 2018-04-26
SMT201400029B (it) 2014-07-07
DK2727588T3 (en) 2018-12-10
CN105997969A (zh) 2016-10-12
SG192968A1 (en) 2013-09-30
US20130085122A1 (en) 2013-04-04
ZA201306039B (en) 2014-10-29
PL2560631T3 (pl) 2014-06-30
MX340568B (es) 2016-07-14
EP3332781A1 (en) 2018-06-13
US9144558B2 (en) 2015-09-29
RS53227B (en) 2014-08-29
US9820978B2 (en) 2017-11-21
EP2680835B1 (en) 2018-02-07
PT2560631E (pt) 2014-02-24
NZ614184A (en) 2015-08-28
HK1182615A1 (en) 2013-12-06
JP6416328B2 (ja) 2018-10-31
WO2012117075A3 (en) 2012-12-13
SI2796132T1 (sl) 2018-09-28
CN105997969B (zh) 2022-03-25
WO2012117075A2 (en) 2012-09-07
JP2014510069A (ja) 2014-04-24
EP2680835A2 (en) 2014-01-08
EP2796132A1 (en) 2014-10-29
IL261725A (en) 2018-10-31
CA2828765C (en) 2019-07-30
KR101918745B1 (ko) 2018-11-15
BR112013022112B1 (pt) 2021-09-28
US20170231958A1 (en) 2017-08-17
CA2828765A1 (en) 2012-09-07
LT2727588T (lt) 2019-01-25
ES2845204T3 (es) 2021-07-26
CN103596562A (zh) 2014-02-19
US20160000736A1 (en) 2016-01-07
JP5987008B2 (ja) 2016-09-06
TR201809351T4 (tr) 2018-07-23
EA023277B1 (ru) 2016-05-31
KR20140038378A (ko) 2014-03-28
US20140378440A1 (en) 2014-12-25
AU2012222351A1 (en) 2013-08-29
ES2678794T3 (es) 2018-08-17
SI2727588T1 (sl) 2019-03-29
EA201300974A1 (ru) 2014-01-30
RS58114B1 (sr) 2019-02-28
AU2012222351B2 (en) 2017-05-18
JP2017193562A (ja) 2017-10-26

Similar Documents

Publication Publication Date Title
CY1120369T1 (el) Θεραπεια νευρολογικων διαταραχων βασει βακλοφαινης και ακαμπροσατης
EA201690501A1 (ru) Новые композиции для лечения неврологических расстройств
EA201300975A1 (ru) Новые композиции для лечения неврологических заболеваний
HK1258231A1 (zh) 治療阿爾茨海默氏症、亨廷頓氏症、孤獨症和其他障礙的方法
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX356800B (es) Anticuerpo tau humanizado.
WO2016033439A3 (en) Compositions and methods for the treating an inflammatory disease or disorder
UA115122C2 (uk) Cd3-зв&#39;язувальна молекула, здатна до зв&#39;язування з cd3 людини і cd3, що не є людським
BR112014011404A2 (pt) moléculas de anticorpos com especificidade para o ox40 humano
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
BR112013017745A2 (pt) métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho
BR112015000329A2 (pt) formulações de diclofenac
CY1118966T1 (el) Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος
EA201691602A1 (ru) Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств
BR112015021681A2 (pt) proteínas de ligação para pcsk9
WO2014160871A3 (en) Methods and agents for treating alzheimer&#39;s disease
BR112015011798A2 (pt) métodos e composições para tratar doenças neurodegenerativas
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
CA2851761C (en) Method of diagnosis, prognostic or treatment of neurodegenerative diseases
DOP2018000001A (es) Moléculas de fusión
MX2019001421A (es) Composiciones de reelina para el tratamiento de trastornos neurologicos.
CY1124821T1 (el) Ιγμεσινη για χρηση στη θεραπεια της νοσου του αλτσχαιμερ
MX2016000724A (es) Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas.
WO2014111525A3 (en) Combination therapies for treating nervous system diseases
GB201206761D0 (en) Anti-atherogenic peptides